Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma

CONCLUSION: Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.PMID:38657575 | DOI:10.1159/000539066

Source: Acta Haematologica - April 24, 2024 Category: Hematology Authors: Taku Kikuchi Nobuhiro Tsukada Kodai Kunisada Moe Nomura-Yogo Yuki Oda Kota Sato Tomomi Takei Mizuki Ogura Yu Abe Kenshi Suzuki Tadao Ishida Source Type: research